SGLT2 inhibitors: Dapagliflozin, Canagliflozin and Empagliflozin are new class of antidiabetics which lower blood glucose levels by preventing renal tubular glucose absorption. Renal glycosuria with normal blood glucose levels is common side effect. Prescribing trend: Being new class highly prescribed. Drawbacks: By causing renal glycosuria make patient more prone to suffer from UTI. A Case Report: A 60 years old diabetic woman was prescribed dapagliflozin 10 mg daily in addition to treatment with metformin and glimepiride.
She had symptoms of urinary tract infection. She was advised investigations urine routine analysis, urine c/s, cbc and blood glucose levels. E coli growth was detected and urine glucose +++. Cost of antibiotics, cost of c/s after stopping antibiotics, increased number of hospital visits and doctors fee plus being away from the occupation during this period of…
